Research map: Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

Back to the article

Papers in this map

  1. Continuous cultures of fused cells secreting antibody of predefined specificity · Georges Köhler · 1975 · 17298 citations · Cited by this paper
  2. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies · 2025 · Related
  3. Integrins · Richard O. Hynes · 2002 · 8647 citations · Cited by this paper
  4. Epilepsy: Epidemiology, Molecular Pathogenesis, and Clinical Management · 2026 · Related
  5. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer · Sunil Verma · 2012 · 3861 citations · Cited by this paper
  6. Preoperative Albumin Infusion Reduced Pulmonary Complications in Elderly Patients With Hypoalbuminemia Undergoing Cardiac Surgery: A Single‐Center, Randomized, Double‐Blind, Controlled Pilot Trial · 2026 · Related
  7. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer · Oliver A. Sartor · 2021 · 2844 citations · Cited by this paper
  8. CD8 + Tissue‐Resident Memory T Cells in Health and Disease · 2026 · Related
  9. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer · Shanu Modi · 2022 · 2707 citations · Cited by this paper
  10. MYC in Oncogenesis and Therapeutic Implications · 2026 · Related
  11. Aptamers as therapeutics · Anthony D. Keefe · 2010 · 2301 citations · Cited by this paper
  12. Lymphatic Endothelial Cells in Health and Disease · 2026 · Related
  13. Strategies and challenges for the next generation of antibody–drug conjugates · Alain Beck · 2017 · 2288 citations · Cited by this paper
  14. Nicotinamide N‐Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma · 2026 · Related
  15. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer · Shanu Modi · 2019 · 2027 citations · Cited by this paper
  16. Markers Predicting Cure With Combinatorial Treatment in a Mouse Model of Latent Autoimmune Diabetes in Adults · 2026 · Related
  17. Polymer conjugates as anticancer nanomedicines · Ruth Duncan · 2006 · 1964 citations · Cited by this paper
  18. Unlocking the potential of bispecific ADCs for targeted cancer therapy · 2024 · Related
  19. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics · Uttpal Anand · 2022 · 1817 citations · Cited by this paper
  20. Antibody–drug conjugates in lung cancer: current landscape and future perspectives · 2025 · Related
  21. Microtubule-binding agents: a dynamic field of cancer therapeutics · Charles Dumontet · 2010 · 1734 citations · Cited by this paper
  22. Antibody drug conjugate: the “biological missile” for targeted cancer therapy · Zhiwen Fu · 2022 · 1638 citations · Cited by this paper
  23. Paul Ehrlich's magic bullet concept: 100 years of progress · Klaus Strebhardt · 2008 · 1446 citations · Cited by this paper
  24. Replacing the complementarity-determining regions in a human antibody with those from a mouse · Peter Jones · 1986 · 1423 citations · Cited by this paper
  25. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia · Hagop M. Kantarjian · 2016 · 1415 citations · Cited by this paper
  26. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index · Jagath Reddy Junutula · 2008 · 1390 citations · Cited by this paper
  27. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer · Kohei Shitara · 2020 · 1352 citations · Cited by this paper
  28. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review) · Volker Schirrmacher · 2018 · 1310 citations · Cited by this paper
  29. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate · Kevin J. Hamblett · 2004 · 1253 citations · Cited by this paper
  30. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 · Yusuke Ogitani · 2016 · 1193 citations · Cited by this paper
  31. Cell-Penetrating Peptides: From Basic Research to Clinics · Giulia Guidotti · 2017 · 1167 citations · Cited by this paper
  32. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  33. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study · Sylvie Castaigné · 2012 · 1018 citations · Cited by this paper
  34. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse · Eric L. Sievers · 2001 · 901 citations · Cited by this paper
  35. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study · Sagar Lonial · 2019 · 817 citations · Cited by this paper
  36. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Laurie Helen Sehn · 2019 · 785 citations · Cited by this paper
  37. Natural killer cells in antitumour adoptive cell immunotherapy · Tamara J. Laskowski · 2022 · 784 citations · Cited by this paper
  38. Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity · Yusuke Ogitani · 2016 · 752 citations · Cited by this paper
  39. The immunogenicity of humanized and fully human antibodies · Fiona Harding · 2010 · 746 citations · Cited by this paper

Source: OpenAlex (CC0)